The immunostimulating complex or 'iscom' was first described 20 years ago as an antigen delivery system with powerful immunostimulating activity. Iscoms are cage-like structures, typically 40 nm in diameter, that are comprised of antigen, cholesterol, phospholipid and saponin. ISCOM-based vaccines have been shown to promote both antibody and cellular immune responses in a variety of experimental animal models. This review focuses on the evaluation of ISCOM-based vaccines in animals over the past 10 years, as well as examining the progress that has been achieved in the development of human vaccines based on ISCOM adjuvant technology.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1440-1711.2005.01319.x | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!